Vir Biotechnology, Inc. (VIR)

Market Cap	634.15M
Revenue (ttm)	19.00M
Net Income (ttm)	-550.23M
Shares Out	138.92M
EPS (ttm)	-4.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,108,467
Open	4.420
Previous Close	4.355
Day's Range	4.360 - 4.630
52-Week Range	4.155 - 14.450
Beta	1.18
Analysts	Strong Buy
Price Target	30.25 (+562.65%)
Earnings Date	Aug 6, 2025

About VIR

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 11, 2019
• Employees: 408
• Stock Exchange: NASDAQ
• Ticker Symbol: VIR
• Website: https://www.vir.bio

Financial Performance

In 2024, Vir Biotechnology's revenue was $74.21 million, a decrease of -13.90% compared to the previous year's $86.18 million. Losses were -$521.96 million, -15.14% less than in 2023.

Analyst Forecast

According to 8 analysts, the average rating for VIR stock is "Strong Buy." The 12-month stock price target is $30.25, which is an increase of 562.65% from the latest price.

Price Target

$30.25

(562.65% upside)

Analyst Consensus: Strong Buy